Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progre

[News]

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

More... (http://www.news-medical.net/news/20131216/Combination-of-ramucirumab-and-docetaxel-fails-to-delay-advanced-breast-cancer-progression.aspx)